首页 > 市场调查报告书 > 製药

消化器

全球炎症性肠病治疗市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、增长、趋势和预测

市场调查报告书

商品编码

1342882

全球炎症性肠病治疗市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、增长、趋势和预测

Global Inflammatory Bowel Disease Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年08月01日 | 出版商:

Value Market Research | 英文 201 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球炎症性肠病治疗市场的需求预计将从 2022 年的 270 亿美元增至 2030 年的近 501.8 亿美元，2023-2030 年研究期间复合年增长率为 7.13%。

炎症性肠病 (IBD) 是指肠道或消化道发炎的几种慢性疾病。消化道和肠道均受到两种类型 IBD 的影响。一些治疗方法可以帮助控制这种慢性疾病。 IBD 治疗的目标是减少炎症。在最好的情况下，这可能会导致症状缓解、长期缓解并降低并发症的风险。手术和药物治疗用于治疗 IBD。

市场动态：

由于生活方式、社会和环境变化等多种因素，溃疡性结肠炎和克罗恩病的患病率在全球范围内不断上升，最终将推动炎症性肠病治疗市场的发展。此外，发达国家更高的疾病诊断率和报销政策促进了市场的扩张，早期疾病诊断变得更加重要。此外，随着人们意识到生物製剂、皮质类固醇等药物的优势，炎症性肠病的治疗正在蓬勃发展。同样，随着越来越多的人受到 IBD 影响，用于治疗炎症性肠病的有前途的管道药物的日益普及将推动市场增长，从而增加对有效治疗替代方案的需求。

该研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球炎症性肠病治疗市场的各个细分市场进行了包容性评估。炎症性肠病治疗行业的增长和趋势为本研究提供了整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲炎症性肠病治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。炎症性肠病治疗市场的主要参与者包括艾伯维公司、百健公司、强生服务公司、安进公司、UCB SA、诺华公司、武田製药有限公司、默克公司、辉瑞公司、莉莉。本节包含竞争格局的整体视图，包括各种战略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何定制要求，请写信给我们。我们的研究团队可以根据您的需求提供定制报告。

简介 - 市场动态
市场驱动因素
市场限制
机会
行业动态
波特五力分析
市场吸引力分析
- 按类型分類的市场吸引力分析
- 按药品类别分類的市场吸引力分析
- 按给药途径进行的市场吸引力分析
- 按分销渠道分類的市场吸引力分析
- 市场吸引力分析：按地区

第 4 章：价值链分析

价值链分析
原材料分析
- 原材料清单
- 原料厂商清单
- 主要原材料价格走势
潜在买家名单
营销渠道
- 直效行销
- 间接营销
- 营销渠道发展趋势

第 5 章：COVID-19 爆发的影响分析

第 6 章：全球炎症性肠病治疗市场分析：按类型

按类型概述
历史和预测数据
按类型分析
克罗恩病
溃疡性结肠炎

第 7 章：全球炎症性肠病治疗市场分析：按药物类别

按药物类别概述
历史和预测数据
按药物类别分析
氨基水杨酸盐
皮质类固醇
肿瘤坏死因子抑製剂
白细胞介素抑製剂
抗整合素
JAK抑製剂
其他的

第 8 章：全球炎症性肠病治疗市场分析：按给药途径

按给药途径概述
历史和预测数据
按给药途径分析
口服
可注射

第 9 章：全球炎症性肠病治疗市场分析：按分销渠道

按分销渠道分類的概览
历史和预测数据
按分销渠道分析
医院药房
零售药房
网上药房

第 10 章：全球炎症性肠病治疗市场分析：按地理位置

区域展望
介绍
北美销售分析
- 概述、历史和预测销售分析
- 北美按细分市场销售分析
- 北美按国家/地区销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概述、历史和预测销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家/地区销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 意大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概述、历史和预测销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳大利亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概述、历史和预测销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家/地区销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概述、历史和预测销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙特阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 11 章：炎症性肠病治疗公司的竞争格局

炎症性肠病治疗市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 12 章：公司简介

顶级公司股票分析
市场集中度
AbbVie Inc.

公司简介
公司收入
产品
最近的发展

Biogen

公司简介
公司收入
产品
最近的发展

Johnson & Johnson Services Inc.

公司简介
公司收入
产品
最近的发展

Amgen Inc.

公司简介
公司收入
产品
最近的发展

UCB SA

公司简介
公司收入
产品
最近的发展

Novartis AG

公司简介
公司收入
产品
最近的发展

Takeda Pharmaceutical Company Limited

公司简介
公司收入
产品
最近的发展

Merck & Co. Inc.

公司简介
公司收入
产品
最近的发展

Pfizer Inc.

公司简介
公司收入
产品
最近的发展

Lilly

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细信息和近期发展视情况而定，或者如果是私营公司，则可能不包括在内

简介目录图表

Product Code: VMR11219393

The global demand for Inflammatory Bowel Disease Treatment Market is presumed to reach the market size of nearly USD 50.18 BN by 2030 from USD 27 BN in 2022 with a CAGR of 7.13% under the study period 2023 - 2030.

Inflammatory bowel disease (IBD) refers to several chronic disorders where the gut or digestive tract is inflamed. The digestive and intestinal tract is affected by both types of IBD. Some treatments can help with the management of this chronic illness. The goal of IBD treatment is to reduce inflammation. In the best-case situation, this might lead to symptom relief, long-term remission, and a decreased risk of complications. Surgery and drug therapy are used to treat IBD.

MARKET DYNAMICS:

The prevalence of ulcerative colitis and Crohn's disease is rising globally due to various factors, including lifestyle, societal and environmental changes, that will eventually fuel the market for inflammatory bowel disease treatment. In addition, a greater disease diagnosis rate and reimbursement policies in developed nations boost the market's expansion as early disease diagnosis becomes more important. Furthermore, inflammatory bowel disease treatment is surging as people become aware of the advantages of medications like biologics, corticosteroids, and others. Again, the increasing prevalence of promising pipeline medicines for inflammatory Bowel Disease treatment will propel market growth as more individuals become affected by IBD, increasing the demand for effective treatment alternatives.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of inflammatory bowel disease treatment. The growth and trends of inflammatory bowel disease treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the inflammatory bowel disease treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Crohn'S Disease
Ulcerative Colitis

By Drug Class

Aminosalicylates
Corticosteroids
TNF Inhibitors
IL Inhibitors
Anti-Integrin
JAK Inhibitors
Others

By Route Of Administration

Oral
Injectable

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Inflammatory Bowel Disease Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the inflammatory bowel disease treatment market include AbbVie Inc., Biogen, Johnson & Johnson Services Inc., Amgen Inc., UCB S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Pfizer Inc., Lilly. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . INFLAMMATORY BOWEL DISEASE TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Drug Class
- 3.7.3 Market Attractiveness Analysis By Route Of Administration
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY TYPE

6.1 Overview by Type
6.2 Historical and Forecast Data
6.3 Analysis by Type
6.4 Crohn's Disease Historic and Forecast Sales by Regions
6.5 Ulcerative Colitis Historic and Forecast Sales by Regions

7 . GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY DRUG CLASS

7.1 Overview by Drug Class
7.2 Historical and Forecast Data
7.3 Analysis by Drug Class
7.4 Aminosalicylates Historic and Forecast Sales by Regions
7.5 Corticosteroids Historic and Forecast Sales by Regions
7.6 TNF inhibitors Historic and Forecast Sales by Regions
7.7 IL inhibitors Historic and Forecast Sales by Regions
7.8 Anti-integrin Historic and Forecast Sales by Regions
7.9 JAK inhibitors Historic and Forecast Sales by Regions
7.10. Others Historic and Forecast Sales by Regions

8 . GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

8.1 Overview by Route Of Administration
8.2 Historical and Forecast Data
8.3 Analysis by Route Of Administration
8.4 Oral Historic and Forecast Sales by Regions
8.5 Injectable Historic and Forecast Sales by Regions

9 . GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

9.1 Overview by Distribution Channel
9.2 Historical and Forecast Data
9.3 Analysis by Distribution Channel
9.4 Hospital Pharmacy Historic and Forecast Sales by Regions
9.5 Retail Pharmacy Historic and Forecast Sales by Regions
9.6 Online Pharmacy Historic and Forecast Sales by Regions

10 . GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE INFLAMMATORY BOWEL DISEASE TREATMENT COMPANIES

11.1. Inflammatory Bowel Disease Treatment Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF INFLAMMATORY BOWEL DISEASE TREATMENT INDUSTRY

12.1. Top Company Share Analysis
12.2. Market Concentration Rate
12.3. AbbVie Inc.
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Biogen
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. Johnson & Johnson Services Inc.
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. Amgen Inc.
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. UCB S.A.
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. Novartis AG
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Takeda Pharmaceutical Company Limited
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Merck & Co. Inc.
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments
12.11. Pfizer Inc.
- 12.11.1. Company Overview
- 12.11.2. Company Revenue
- 12.11.3. Products
- 12.11.4. Recent Developments
12.12. Lilly
- 12.12.1. Company Overview
- 12.12.2. Company Revenue
- 12.12.3. Products
- 12.12.4. Recent Developments